3Sixty Biopharmaceuticals (Pty) Ltd is at varying stages of launching and bringing to market product technologies
that respond to some of mankind’s most challenging disease; these include

This portfolio is anchored around anti-retrovirals (ARVs) drugs for HIV and Tuberculosis (TB). ARVs with unique compelling benefits targeting poorly met clinical needs with a strong focus on improving demographic relevance are in pre-commercialisation phase (i.e. phase IV clinical trials) The company focus on TB is on treatment shortening using novel drug delivery systems
A variety of skin conditions are pursued using a combination of new active pharmaceutical ingredients coupled with new to the world delivery systems. Clinical trials are in final stages
Italian Trulli A large percentage of women endure excessive bleeding accompanied by severe pain during their menstrual cycles. Assets are identified which results in a vastly improved patient experience based on herbal extracts

Click here for official SA information regarding Covid-19

PHP Warning: is_readable(): open_basedir restriction in effect. File(C:\Inetpub\vhosts\3sixtybiopharma.co.za\httpdocs/wp-content/plugins/C:\Inetpub\vhosts\3sixtybiopharma.co.za\httpdocs\wp-content\plugins\disable-comments-rb/languages/disable-comments-rb-en_US.mo) is not within the allowed path(s): (C:/Inetpub/vhosts/3sixtybiopharma.co.za\;C:\Windows\Temp\) in C:\Inetpub\vhosts\3sixtybiopharma.co.za\httpdocs\wp-includes\l10n.php on line 649